This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
by Zacks Equity Research
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading day.
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
by Zacks Equity Research
Roche has collaborated with Zealand Pharma to develop and commercialize petrelintide for obesity
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
by Zacks Equity Research
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
3 Top Cancer Biotechs to Keep An Eye On in 2025
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $912.76, moving -1.82% from the previous trading session.
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%
by Zacks Equity Research
NVO offers Wegovy at a discounted price of $499 per month, which is less than half of its listed price.
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
by Shaun Pruitt
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
by Zacks Equity Research
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More
by Kinjel Shah
LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.
Top Research Reports for Amazon, Eli Lilly & S&P Global
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co. (LLY) and S&P Global Inc. (SPGI), as well as a micro-cap stock CVD Equipment Corporation (CVV).
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.